Denali Therapeutics is a biotechnology company developing therapies for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS. Its platform focuses on delivering large-molecule drugs across the blood–brain barrier, a longstanding obstacle in CNS drug development. Programs span genetically defined and broader neurodegenerative indications, often in partnership with larger pharmaceutical firms. The business is research- and pipeline-driven rather than commercial product sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -124.1 | — |
| Q3 2025 | 0 | — | -126.9 | — |
| Q4 2025 | 0 | — | -128.6 | — |
| Q1 2026 | 0 | — | -128.4 | — |
| Q2 2026 | 3.6 | — | -127.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Parabilis Medicines, Inc. (PBLS), Firefly Aerospace Inc. (FLY), Liftoff Mobile, Inc. (LFTO), Acadia Healthcare Company, Inc. (ACHC), Almonty Industries Inc. (ALM), Huron Consulting Group Inc. (HURN)